The influence of intervening on the pharmaceutical consultation targeting outpatients with advanced non-small cell lung cancer receiving erlotinib treatment
S Nishibe-Toyosato, Y Ando, Y Goto… - Biological and …, 2021 - jstage.jst.go.jp
Erlotinib is used to treat advanced non-small-cell lung cancer (NSCLC), the common serious
adverse events are skin disorders. The dose intensity of erlotinib should be maintained as …
adverse events are skin disorders. The dose intensity of erlotinib should be maintained as …